Article
Propofol overcome Tamoxifen resistance in breast cancer by modulating tumorogenesis, immune response and metabolism
2024-04-20
Abstract excerpt
Although 70% of estrogen receptor (ER)-positive breast cancer patients benefit from Tamoxifen therapy, the developing resistance to Tamoxifen leads to high rates of metastasis and poor prognosis. Propofol, a commonly used anesthetic, has been shown to inhibit the occurrence and development of breast cancer. However, its role in anti-endocrine resistance in ER-positive breast cancer remains unclear. In this study,...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 9db3f5fb-a5c7-5117-9964-9466f6f56f05
- DOI
- 10.1101/2024.04.15.589641
